MindMed partners with NYU Langone Medical Center to launch training program for psychedelic therapies and medicines

A recent press release announces that "MindMed (a leading psychedelic medicine biotech company) is committing $5 million over a five-year period to the NYU Langone Health Psychedelic Medicine Research Training Program and the future corresponding Center for Psychedelic Medicine at NYU Langone Health. NYU Langone Health will have full and free discretion in using these funds for the development and conduct of the training program and operations of the Center for Psychedelic Medicine. The launch of the Center for Psychedelic Medicine at NYU Langone Health is still subject to additional funding from other undisclosed partners and parties.

The Psychedelic Medicine Research Training Program will be managed by Principal Investigator Michael Bogenschutz, M.D., an expert in clinical trials research and the primary investigator leading the effort towards FDA approval of psilocybin-assisted psychotherapy for Alcohol Use Disorder. The program will be directed by Stephen Ross, M.D., a world leader in advancing research on psychedelic medicine and a prominent addiction psychiatrist."

Previous
Previous

US Psychedelic Medicine Association launches

Next
Next

Broadening your mind to Include others: The relationship between serotonergic psychedelic experiences and maladaptive narcissism.